Fox EJ, Sullivan HC, Gazda SK, Mayer L, O’Donnell L, Melia K, Lake SL. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis Eur J Neurol. 2011 [Epub ahead of print].
Although this drug is not without some serious dangers, It clearly shows that at least the relapsing part of multiple sclerosis is controlled by the activity of white blood cells, “as was shown in animal studies many years ago“
The question will be” if the regulators consider the safety profile acceptable, how much is this drug going to be?”.